Alkermes plc (ALKS) Stock Score, Valuation & Financial Research
Alkermes plc is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 35/100.
Quick answer for ALKS
Alkermes plc currently has a Wall Street Score of 35/100. The stored market price is $45.97. Its financial score is 44/100. Its valuation score is 0/100. The latest WSS change is +0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Alkermes plc does
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extende
ALKS financial snapshot
- Wall Street Score:
- 35/100
- Current price:
- $45.97
- Market capitalization:
- $7.71B
- Revenue:
- $1.67B
- Net income:
- $66.1M
- Free cash flow:
- $480.3M
- Cash:
- $511.5M
- Total debt:
- $1.57B
- EPS:
- 0.40
- P/E ratio:
- 114.1x
- Financial score:
- 44/100
- Valuation score:
- 0/100
- Revenue score:
- 18/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $480.3M, showing positive cash generation.
- The balance sheet shows $511.5M of cash versus $1.57B of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +0.1 points: ALKS increased 0.1 points because overall fundamentals improved.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 44/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research ALKS
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.